| Literature DB >> 22474527 |
Zhe Liu1, Ling Guan, Yan Wang, Cheng-Long Xie, Xian-Ming Lin, Guo-Qing Zheng.
Abstract
Intracerebral hemorrhage (ICH) is an important public health problem with high rates of mortality, morbidity, and disability, but no clinically proven treatment strategy is available to date. Scalp acupuncture (SA) refers to a therapy for treating diseases by needling and stimulating the specific areas of the scalp. The evidence from clinical studies suggested that SA therapy may produce significant benefits for patients with acute ICH. However, the therapeutic mechanisms are yet not well addressed. Therefore, in this paper, we provide a comprehensive overview on the history and mechanisms of SA therapy on acute ICH. Although SA has been practiced for thousands of years in China and could date back to 5 BC, SA therapy for acute ICH develops only in the recent 30 years. The possible mechanisms associated with the therapeutic effects of SA on ICH include the influence on hematoma, brain edema, and blood brain barrier, the products released from haematoma, the immune and inflammatory reaction, focal perihemorrhagic hypoperfusion and hemorheology, neuroelectrophysiology, and so on. At last, the existence of instant effect of SA on acute ICH and its possible mechanisms are presented.Entities:
Year: 2012 PMID: 22474527 PMCID: PMC3296221 DOI: 10.1155/2012/895032
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Brief History of the Development of Scalp Acupuncture.
| Year | Author and/or work | Contribution |
|---|---|---|
| 5 BC | Bian Que's biography | The earliest medical record for the application of SA therapy in China |
| 221 BC–220 AD |
| Establishment of the TCM theory basis for SA therapy. |
| 220 AD–1950 AD | There were rich records of SA therapy in the medical books. | SA therapy developed through different generations, but it still belonged to the traditional acupuncture system. |
| 1950's | SA became one part of micropuncture systems. | SA began to form up an independent system. |
| 1970's | Jiao Shunfa SA therapy, Fang Yunpeng SA therapy, Zhu Longyu SA therapy, and Zhu Minqing SA therapy, Yamamoto et al. new SA | SA therapy developed rapidly and has formed various scalp acupoint nomenclature systems. |
| 1980's–1990's | WHO Scientific Group on International Acupuncture Nomenclature | The international standard SA lines were approved by scientific group of WHO. |
SA, Scalp Acupuncture. WHO, World Health Organization.
Nomenclature of scalp acupuncture lines by scientific group of WHO.
| Regions | English name and location | Pinyin name | Han character name | Alphan-umeric code |
|---|---|---|---|---|
|
| Middle line of forehead 1 cun from GV 24 straight down along the meridian. | Ézhongxiàn |
| MS1 |
| Lateral line 1 of forehead 1 cun from BL3 straight down along the meridian. | Épángxiàn I |
| MS2 | |
| Lateral line 2 of forehead 1 cun from GB15 straight down along the meridian. | Épángxiàn II |
| MS3 | |
| Lateral line 3 of forehead 1 cun from the point 0.75 cun medial to ST8 straight down. | épángxiàn III |
| MS4 | |
|
| ||||
|
| Middle line of vertex from GV 20 to GV 21 along the midline of head. | Dingzhongxiàn |
| MS5 |
| Anterior oblique line of vertex-temporal from qiánshéncong | Dingniè qiánxiéxiàn |
| MS6 | |
| Posterior oblique line of vertex-temporal from GV 20 obliquely to GB7. | Dingniè hòuxiéxiàn |
| MS7 | |
| Lateral line 1 of vertex 1.5 cun lateral to middle line of vertex, 1.5 cun from BL6 backward along the meridian. | Dingpángxiàn I |
| MS8 | |
| Lateral line 2 of vertex 2.25 cun lateral to middle line of vertex, 1.5 cun from GB17 backward along the meridian. | Dingpángxiàn II |
| MS9 | |
|
| ||||
| Temporal region | Anterior temporal line from GB4 to GB6. | Nièqiánxiàn |
| MS10 |
| Posterior temporal line from GB8 to GB7. | Nièhòuxiàn |
| MS11 | |
|
| ||||
|
| upper-middle line of occiput from GV 18 to GV 17 | Zhenshàng zhèngzhongxiàn |
| MS12 |
| Upper-lateral line of occiput 0.5 cun lateral and parallel to upper-middle line of occiput. | Zhenshàng pángxiàn |
| MS13 | |
| Lower-lateral line of occiput 2 cun from BL9 straight down. | Zhenxià pángxiàn |
| MS14 | |
Brief history of SA therapy for acute intracerebral hemorrhage.
| Year | Author and/or work | Contribution |
|---|---|---|
| 1980's | Some study groups | Began to explore SA therapy for acute ICH. |
| 1992 | Dong et al. 1992 [ | First clinical trial of the SA therapy for acute ICH. |
| 1999 | Li et al. 1999 [ | A well-designed clinical trial to study the therapeutic effect of SA in treating acute ICH and its mechanisms. |
| 2006 | Zheng et al. 2006 [ | A first review of this field entitled “Literature foundation of scalp-acupuncture treatment of ICH and its recent progress in clinical research”. |
| 2009 | Zheng 2009 [ | To provide methodological reference for future mechanism study on stroke study using SA. |
| 2010 | Zheng et al. 2010 [ | A first Meta-analysis of SA therapy for acute hypertensive ICH. |
SA, Scalp Acupuncture. ICH, intracerebral hemorrhage.
Possible mechanisms for treatment of acute ICH with scalp acupuncture.
| Possible targets | Possible mechanisms |
|---|---|
| Influence on hematoma, brain edema and, blood brain barrier | Improve the absorption rate of hematoma, reduce brain edema, diminish cerebral vessel permeability, and promote reparation for BBB damage. |
| Influence on the products released from haematoma | Inhibit the expression of MMP-9, AQP-4, and PAR-1. |
| Influence on the immune and inflammatory reaction | Inhibit the expression of IL-1 |
| Influence on focal perihemorrhagic hypoperfusion and hemorheology | improve energy metabolism, upregulate the activity of hondriosome (Succinate dehydrogenase and Na+-K+-ATPase), reduce the accumulation of lactate acid, delay Glut-1 expression, lower plasma ET level and NSE level, and heighten CGRP level. |
| Influence on neuroelectrophysiology | Relieve the inhibitive generalization of the whole brain neuron function, have bidirectional and beneficial regulation effect on electric activity of pain-reaction neurons, and recover abnormal SEPs. |
| Others | Promote the NCF gene expression, promote the expression of endogenous GDNF, lower the level of serum S-100B, and promote the level of IGF-1. |
BBB, blood-brain barrier. MMP-9, matrix metallopeptidase-9. AQP-4, aquaporin-4. PAR-1, protease-activated receptor-1. IL, interleukin. TNF-α, tumour necrosis factor α. HSP70, heat shock protein 70. Glut-1, glucose transporter-1. ET, endothelin. NSE, neuron specific enolase. CGRP, calcitonin gene-related peptide. SEPs, somatosensory-evoked potentials. NCF, nerve growth factor. GDNF, glial cell line-derived neurotrophic factor. IGF-1, insulin-like growth factor 1.